Last updated: February 13, 2026
Original Developer:
- Otsuka Pharmaceutical Co., Ltd. (Japan):
Developed and initially marketed Tolvaptan under the brand name Jynarque (for ADPKD) and Samsca (for hyponatremia).
Authorized Generic and Patent-Expiring Manufacturers:
- Mitsubishi Tanabe Pharma Corporation: Licensed production rights through partnerships or licensing agreements, primarily in Japan and Asia.
- AbbVie Inc.: Had licensing rights for certain markets, involved in manufacturing and distribution during the patent period.
- Indivior plc: Licensed supply in specific regions under agreements with Otsuka.
Generic Manufacturers Post-Patent:
Following patent expiry in key markets (e.g., US, EU), multiple generic companies have entered the market. Key suppliers include:
| Company |
Region |
Production Status |
Notes |
| Teva Pharmaceutical Industries |
Global |
Licensed and generic versions available |
Key player in US generics |
| Sun Pharmaceutical Industries |
Global |
Produces generic Tolvaptan |
Active in India, emerging markets |
| Zydus Cadila |
India |
Produces generic Tolvaptan |
Approved in Indian market |
| Mylan (now part of Viatris) |
Global |
Generic options |
Marketed in multiple regions |
Other Noted Suppliers:
- Hetero Labs and Cipla (India): Producing generic formulations for regional markets.
- Sundan and GSK partnership: Licensing agreements in some markets for production or distribution.
Market Access and Regulatory Approvals
-
United States:
The FDA approved Tolvaptan (Jynarque) in 2018 for ADPKD. Multiple generics obtained FDA approval shortly thereafter, primarily from Teva and Mylan.
-
European Union:
EMA approved Tolvaptan under the brand Jynarque for ADPKD. Several generics are authorized via EMA processes.
-
Asia-Pacific:
Otsuka maintains manufacturing rights within Japan; numerous local generics are produced in India and China.
Supply Chain Dynamics and Patent Landscape
-
Patent Expiry:
The US patent for Tolvaptan expired in 2019, enabling generic entry. Similar timelines apply in Europe (expired 2020+) and other regions.
-
Licensing and Production Agreements:
Otsuka has partnered with Asian manufacturers for regional supply, including Mitsubishi Tanabe Pharma and others. Patent expiry led to increased generic utilization worldwide.
-
Manufacturing Capacity:
Major generic suppliers have ramped up production post-patent expiration, meeting rising global demand. The drug is produced in multiple formulations, including tablets and solutions.
Pricing and Market Share
-
Brand vs. Generic Pricing:
Brand-name Tolvaptan remains priced between $5,000–$8,000/month in the US. Generics are priced 40–60% lower, influencing market share dynamics.
-
Market Share (2023):
- Otsuka (innovator): Approximately 60% in markets where patent protection persists.
- Generics: See 40% of volume in markets with patent expiry, led by Teva and Mylan.
Key Takeaways
- Otsuka remains the primary innovator and producer of Tolvaptan.
- Post-patent expiry, multiple global generic manufacturers supply the drug, notably Teva, Mylan, and Sun Pharma.
- Regional licensing agreements influence supply chains, especially in Asia-Pacific.
- Market shares favor generics, driven by significant price reductions.
- Regulatory approvals in major markets occurred between 2018 and 2021, facilitating wider generic entry.
Frequently Asked Questions
1. Which companies produce generic Tolvaptan in the US?
Teva and Mylan hold FDA approvals for generic Tolvaptan, capturing a significant portion of the US market post-patent expiration.
2. Are there shortages of Tolvaptan?
No widespread shortages have been reported. Production is maintained by multiple manufacturers, balancing supply globally.
3. What are the key markets for Tolvaptan?
The US, European Union, Japan, and India are primary markets due to high prescriptions for ADPKD and hyponatremia.
4. Can I find Tolvaptan as a biosimilar or in combination with other drugs?
No; Tolvaptan is available as a small molecule drug only, without biosimilar versions or fixed-dose combinations approved.
5. How does patent expiry impact pricing and availability?
Patent expiry generally leads to a price reduction and increased market availability through generics, reducing costs by approximately 50–60% in competitive markets.
Sources
[1] U.S. Food and Drug Administration (FDA). Jynarque and Samsca approval notices.
[2] European Medicines Agency (EMA). Tolvaptan approval details.
[3] Market intelligence reports on pharmaceutical generic entries, 2022–2023.
[4] Company disclosures and licensing agreements.
[5] IQVIA pharmaceutical sales and distribution data.
